Skip to main content
Novartis
language-selector-globe
Choose Location
  • Americas
  • International
  • Asia Pacific
  • Europe
  • Middle East & Africa
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Global | English
Novartis Foundation | English
Australia | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
United Kingdom | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe
Choose Location
Americas International Asia Pacific Europe Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
United Kingdom | English
United States | English
    • About 
      • Board of Directors 
        • Giovanni Caforio 
        • Simon Moroney 
        • Nancy C. Andrews 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth (Liz) Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Elizabeth McNally 
        • John D. Young 
        • Charlotte Pamer-Wieser 
      • Executive Committee 
        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Patrick Horber 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Lutz Hegemann 
        • Teresa Jose 
        • Michelle Weese 
      • Products 
      • Therapeutic areas 
        • Cardiovascular, renal and metabolic 
        • Immunology 
        • Neuroscience 
        • Oncology 
      • People and culture 
      • Inclusion 
        • Promoting inclusion 
        • Building belonging 
        • Parental leave 
        • Caring for the mental health and wellbeing of our people 
      • Novartis Gene Therapies 
      • Manufacturing 
      • Quality 
        • Audit program 
        • Novartis quality management system (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      • Novartis and the European Union (EU) 
      • Awards and recognition 
      Mother and daughter cuddling on a bed in a kids room

      About

      Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 296 million people worldwide.

    • Patients and caregivers 
      • Novartis commitment to patients and caregivers 
      • Diseases 
      • Patient organization funding 
      • Patients perspectives stories 
      Adult daughter talking to her senior parents on a bench in a park

      Patients and caregivers

      Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.

    • Healthcare professionals 
      • Medical congresses and events 
        • ASCO Annual Meeting 
      • Products 
      • Novartis pipeline 
      • Managed access programs 
        • Zolgensma® Global Managed Access Program (gMAP) 
      • Novartis external funding 
      • Healthcare professional resources by country 
      • Investigator-initiated trials / studies 
      • Novartis medical information 
        • Submit medical enquiry 
      Doctor discussing illness with patient in an office

      Healthcare professionals

      Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.

    • Research and development 
      • Technology platforms 
      • Research disease areas 
        • Cardiovascular and metabolic disease research at Novartis 
        • DAx: exploratory disease research at Novartis 
        • Global Health disease area research at Novartis 
        • Immunology disease research at Novartis 
        • Neuroscience research at Novartis 
        • Oncology research at Novartis 
      • Novartis pipeline 
      • Research collaborations 
      • Collaborations 
      A female research scientist in a lab looking at a sample

      Research & development

      Discover how Novartis turns breakthrough science into transformative, high-value treatments.
       

    • ESG 
      • Access 
        • Creating sustainable business models 
        • Value-based pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis access principles 
        • Novartis oncology access 
        • Patents and licensing 
      • Environmental sustainability 
        • Climate 
        • Nature - Waste 
        • Nature - Water 
      • Ethics, risk and compliance 
        • Ethical behavior 
        • Compliance 
        • Human rights 
        • Learning and engagement 
        • Integrated risk assurance 
      • Global health 
        • Pandemic preparedness 
        • Avoidable blindness 
        • Chagas disease 
        • Leprosy 
        • Malaria 
        • Sickle cell disease (SCD) 
        • Novartis Foundation 
      • Inclusion 
      • ESG index 
      • Reporting and transparency hub 
        • ESG rating performance 
        • Targets 
        • Patient organization funding 
        • Payments to healthcare professionals 
        • Public policy 
        • A living wage 
        • A safe workplace 
        • Animal research 
      Family and friends having a party at home

      Environmental, social and governance

      Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report.

    • Investors 
      • Event calendar 
      • Financial data 
        • Novartis annual results 
        • Novartis quarterly results 
        • Novartis SEC filings 
        • Product sales 
        • Fixed-income securities 
        • Expected currency impact 
      • Share data and analysis 
        • Share monitor 
        • Dividend information 
        • Share ownership 
        • Share overview 
        • Return on investment calculator 
      • Shareholder information 
        • General Meetings 
        • American Depositary Receipts (ADR) 
        • Share buyback 
        • Frequently asked questions 
      • Company overview 
        • Corporate governance 
      • Reporting and transparency hub 
        • Reporting archive 
        • ESG rating performance 
        • Publications order form 
      • ESG 
      Business woman working on her laptop in a bright atmosphere

      Investors

      Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.

    • News 
      • Newsroom 
      • Media library  
      • Stories 
      • Subscribe 
      • Events 
      Overhead view of a meeting room with people in the foreground and screens in the background

      News

      Information for journalists including press releases, statements, stories, multimedia resources and more.

    • Careers 
      • Career search 
      • Our business functions 
        • Careers in research and development 
        • Careers in operations 
        • Careers in commercial and sales 
        • Careers in global functions 
      • Why Novartis 
      • Career hub 
        • Temporary contracts 
      • Early careers 
        • Graduates 
        • Students 
        • US Biomedical Research internship programs 
        • Community exploration and learning lab (CELL) 
      Two business people

      Careers

      Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.

    • Clinical trials 
    • Partnering 
    • Supplier portal 
    • Report side effects 
    • Contacts 
    Grandmother, mother and daughter smiling and laughing on a beach

    Home

    Working together, we can reimagine medicine to improve and extend people’s lives.

Disease Eradication

Disease Eradication

Tags Archive Navigation
  • All
  • Careers
  • Featured News
  • In the News
  • Media Releases
  • Story
icon
  • Press Release
    May 18, 2021
    Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
  • Press Release
    Jun 18, 2020
    Novartis expands Africa Sickle Cell Disease program to Uganda and Tanzania
  • Story
    Jul 31, 2014
    New drugs could offer hope for malaria patients
  • Story
    Oct 05, 2017
    Talking to: Patrice Matchaba, Global Head of Corporate Responsibility for Novartis
  • Story
    Sep 10, 2015
    Malaria fighter rides bicycle into battle with disease
  • Story
    Apr 13, 2016
    A life dedicated to fighting malaria
  • Story
    Apr 08, 2014
    Sight savers jet to the rescue
  • Story
    Aug 06, 2020
    Ensuring medicine supply to patients during COVID-19
  • Story
    Apr 24, 2019
    Asian health experts call for final push to wipe out deadliest form of malaria
  • Story
    Apr 22, 2014
    2 million kids receive malaria medicine
  • Story
    Apr 24, 2020
    A visual tour of scientific strategies for combating coronavirus
  • Story
    Oct 27, 2013
    Disease pathways: A key to new drug discovery

Pagination

  • ‹ Previous page
  • 1
  • 2
  • › Next page

Novartis

Working together
  • Patients and caregivers
  • Healthcare professionals
  • Researchers
  • Job seekers
  • Journalists
  • Investors
Topics
  • Q2 2025
  • Access
  • ESG
  • SpeakUp
Explore
  • Pipeline
  • Products
  • Clinical trials
  • Partnering
  • Events
Therapeutic areas
  • Cardiovascular, renal and metabolic
  • Immunology
  • Neuroscience
  • Oncology
Footer Bottom
© 2025 Novartis AG
  • Terms of use
  • Privacy
  • Cookie settings
  • Contacts
  • Locations
  • Site map
  • Open source
  • Web accessibility
Novartis Site Directory
This site is intended for a global audience